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Summary.-Adriamycin and cyclophosphamide are active agents in human and
experimental tumours. Using the L1210 murine leukaemia, their effectiveness
alone and in combination was studied. The combination is highly synergistic in
this tumour, resulting in a greater than5000 survival rate when the agents used alone
at optimal doses are not curative. DNA synthesis by tumour cells is substantially
inhibited and the total ascitic population much reduced. In contrast, DNA synthesis
in sensitive host tissues is less disturbed. There is no major difference in the
pharmacology of the agents whether given alone or in combination. In very
advanced disease the combination is no better than treatment with cyclophosphamide
alone. The combination of adriamycin and melphalan in L1210 leukaemia also
produces superior results to those obtained using either drug alone at its optimal
dosage.
CYCLOPHOSPHAMIDE (CTX), an alky-
lating agent with activity against a wide
range ofexperimental andhumantumours,
has pronounced effects against the L1210
transplantable leukaemia, even in rela-
tively advanced disease (Lane, 1959).
L-phenylalanine mustard (Melphalan,
L-PAM) is also active in L1210, although
this agent has been less thoroughly studied
than CTX (Goldin and Carter 1973).
More recently, the anthracyclene drugs
have been shown to have definite but
limited activity against this tumour
(Hoshino et al., 1972). Of the anthracyc-
lenes, adriamycin (ADR) is clearlysuperior
to daunorubicin in L1210 and most other
experimental tumours (Sandberg et al.,
1970; Di Marco and Lenaz, 1973) and in
most human malignancies (Bonadonna
et al., 1970).
Recent reports on the use of the com-
bination of CTX and ADR have been
encouraging, both in human studies
(Salmon and Jones, 1974; Muggia et al.,
1974; Jones, Durie and Salmon, 1975;
Parker et al., 1975), and in several animal
systems (Wodinsky, Swiniarski and
Venditti, 1974; Corbett et al., 1975).
The purpose ofthisstudywastofurther
evaluate this combination in L1210 leu-
kaemia with respect to (1) the extent of
disease, (2) inhibition of normal and
leukaemic cell DNA synthesis by the
combination, and (3) to investigate the
alkylating agent employed.
MATERIALS AND METHODS
The L1210 leukaemia was obtained from
Mr I. Wodinsky, A.D. Little, Inc., Cambridge,
Mass. and has been maintained in our lab-
oratories by serial passage. Groups of male
BDF1 mice (Jackson Memorial Laboratories,
Bar Harbor, Maine) weighing 25-30 g were
used. The animals were housed in plastic
cages, kept at a constant temperature and
provided with water and laboratory chow
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ad libitum. Ascitic cell suspensions were
prepared in cold sterile saline and all tumour
inocula were made in 01 ml volumes. All
animals were implanted with 105 cells intra-
peritoneally and treatment was by single
intraperitoneal injection on Day 4 following
tumour implantation, except for 2 experi-
ments in which treatment was given on
Day 6 or Day 8 following implantation.
CTX was obtained from Mead, Johnson
Laboratories, Evansville, Indiana; L-PAMI
was obtained from Burroughs Wellcome
Company, Research Triangle Park, North
Carolina and ADR from Farmitalia, Milan.
Solutions were made up in sterile water or
ethyl alcohol (L-PAM) and used immediately
in all cases.
For the experiments designed to investi-
gate DNA synthesis during treatment, a
tritiated thymidine labelling technique was
used. Groups of 3 &nimals were killed by
cervical dislocation at various timegfollowing
treatment. Thirty minutes before killing,
tritiated thymidine (specific activity 6-9 Ci/
mmol, New England Nuclear, Boston, Mass.)
was injected intraperitoneally in a volume
of0 5 ml (total dose50 4uCi/animal). Ascites,
small intestine and both femora were removed
and DNA extractions were made from these
tissues following themethod ofBurton (1956).
The amount of DNA in each sample was
read colourimetrically and an aliquot was
also added to Aquasol scintillation fluid
(New England Nuclear, Boston, Mass.) and
read in a Beckman Scintillation counter for
5 min. Results were expressed as disinti-
grations/min/g of DNA.
Total ascitic cell count was performed in
order to confirm that inhibition of DNA
synthesis did in fact lead to cell kill, and also
to follow the progress of tumour growth
during treatment either with a single agent
or the combination. The pbpulations of
tumour cells were studied Wsing the cyto-
fluorograph and these results will be reported
separately.
In order to investigate the tissue distri-
bution of CTX or ADR when given singly or
together, a series of experiments was per-
formed in which tissues were extracted at
various times following treatment with either
a single agent or both drugs in combination.
Groups of animals were treated with ADR
10 mg/kg, CTX 100 mg/kg, or a combination
of these drugs at the same dosage given by
simultaneousintraperitoneal injection. Groups
of 3 animals were killed at various times
following treatment and the livers and ascitic
fluid removed. Ascitic fluid was centrifuged
at 4°C and the supernatant retained for
analysis. The livers were frozen immediately
and maintained in liquid nitrogen until
analysis. The tissues were extracted for ADR
following the method of Yesair et al. (1972)
and alkylating activity was measured
according to the method of Friedman and
Boger (1961), in order to determine the level
of cyclophosphamide activity. In all cases
appropriate tissue blanks were run.
RESULTS
Treatment of L1210 Leukaemia with ADR
and CTX
The anti-tumour effects of ADR and
CTX alone and in combination are shown
in Table I, in which the results of 4 sep-
arate experiments have been pooled.
Long survival was achieved only when the
2 agents were used in combination.
TABLE I.-Effect of Single Drug and
Combination Treatment with ADR or CTX
in L1210 Leukaemia
(All animals treated on Day 4 only)
Treatment (i.p.)
Median day of
death
Controls 11 .0
CTX 100 mg/kg 18-5
CTX 200 mg/kg 20-5
ADR 10 mg/kg 14-0
ADR 20 mg/kg 17*0
ADR 10 mg/kg+
CTX 100 mg/kg >200
*ILS: increased life span.
Long
term
*ILS (*) survivors
- 0/60
68 - 0 0/20
86 - 4 0/10
27 - 3 0/20
54-5 0/10
- 25/45
Dose response for ADR and CTX in com-
bination
The results of a more complete study
from ineffectual to toxic dosage of the
agents are illustrated in Table II. All
animals were treated by single injection
on Day 4 only.
Schedule dependence ofADR and CTX
The agents were administered either
concurrently or separated by varying time
intervals. This was done for a suboptimal
200ADR/CTX AND ADR/L-PAM IN ADVANCED L1210 LEUKAEMIA
TABLE II. Dose-Response for ADR and
CTX Alone and in Combination. Results
Expressed as Increase in Life Span (ILS)
ADR
(mg/kg)
0 2-5 5 0 10-0 20-0
0 +18 +9 +36 +54
50 +27 +64 +54 +91 -36
CTX 100 +54 +91 * * -91
(mg/kg) (8/14) (9/14)
200 +73 +200 * +100 -36
(8/14)
400 +18 + 73 +18 N.D. N.D.
* ILS not available as greater than 500% of
animals survived.
( )=number of surviving animals.
All animals treated by single injection on Day 4
only.
N.D.=Not done.
dosage because the optimal combination
dosage produced so many long survivors
that small schedule differences would
most likely not have been apparent. The
results are shown in Table III. There is
no clear superiority either ofCTX followed
by ADR or vice versa (P>0-2 by chi square
test).
rapidly. Furthermore, the ADR/CTX
combination essentially eliminates DNA
synthesis in L1210 cells whereas eachagent
alone allows significant DNA synthesis to
continue.
TABLE III.-The Effect of DrugSeparation
on CTX/ADR Combinations. Treatment by
i.p. Injection on Day 4 Following 105 Cells
Median day
Treatment (i.p.) of death
Controls
ADR 5 mg/kg
ADR 10 mg/kg
CrX 100 mg/kg
CTX 200 mg/kg
ADR CTX
5 mg/kg 100
mg/kg h after
ADR
+0
+2
+4
+6
+8
+ 24
11
14
15
19
20 5
30
>200
>200
>200
24 5
22
ILS (%)
27 2
36 3
72 7
86 4
173
122 119
Long
term
survivors
0/10
0/10
0/10
0/10
0/10
5/14
8/14
7/14
7/14
3/14
2/7
Combination treatment in very advanced
disease
The agents were administered either
on Day 6 or Day 8 following implantation
oftumour in order to test the combination
against an increasing tumour burden.
The combination treatment is not superior
to treatment with an optimal dose ofCTX
alone although the combination remains
superior to treatment with either drug
alone at the same dose as is used in the
combination. This is shown in Table IV.
Inhibition of DNA synthesis by ADR/CTX
The inhibition of DNA synthesis for
tumour cells and for host cells in vivo is
shown in Fig. 1. Pilot studies confirmed
that on Day 4 following the implantation
of 105 L1210 cells intraperitoneally, the
number of leukaemic cells infiltrating
the marrow was less than 1007 It is clear
that each agent is much more effective
and sustained on tumour cells than host
cells, even those which are dividing
CTX
100 rng/
kg
ADR
5 mg/kg
h after
CTX
+0
+2
+4
+6
+8
+24
24 5
>200
26
23
23 5
27
122
136
109
114
145
5/14
9/14
5/14
4/14
2/14
5/14
TABLE IV.-The Effect of ADR/CTX in
Late Disease
Treatment a
Controls
ADR
10 mg/kg
20 mg/kg
CTX
100 mg/kg
200 mg/kg
ADR
10 mg/kg &
CTX
100 mg/kg
No. of
nimals
25
15 13 18 12 9
15 16 45 15 36
15
15
15
Day 6
Median
day of
death ILS
11 -
Day 8
Median
day of
death ILS
11 -
20 82 20 82
26 136 23 109
24 118 23 109
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*-* ADRIAMYCIN
10 mg/kg
_-R CYCLOPHOSPHAMIDE
100 mg/kg
0-0 ADRIAMYCIN
10 mg/kg and
CYCLOPHOSPHAMIDE
100mg/kg
(A)
(B)
(C)
0 12 24 36
TIME (h)
48 60 72
FIG. 1.-Inhibition of DNA synthesis in small intestine (A), normal-marrow (B), and L1210 cells (C),
by ADR and CTX alone and in combination (ct/min/g DNA, expressed as % control). Note rapid
inhibition of tumour DNA synthesis. In normal marrow recovery from CTX-induced inhibition is
more rapid than that following ADR-induced inhibition.
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Total ascitic cell counts following treatment
All agents were capable ofreducing the
total number of ascitic cells (Fig. 2).
From the latter part of the curve, and
especially from the data point at 72 h
from treatment, it appears that the com-
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bination treatment produces greater
tumour cell kill than the single agent.
Pharmacology of ADR/CTX
Figures 3 and 4 show the levels of
alkylatingactivityand adriamycin equiva-
*-* CYCLOPHOSPHAMIDE
100 mg/kg
0-O ADRIAMYCIN
10 mg/kg
L--. CYCLOPHOSPHAMIDE
100 mg/kg and
ADRIAMYCIN 10 mg/kg
TIME (h) FROM TREATMENT
FIG. 2.-Total ascitic cell count following 105 cells on Day 0. Single agent or combination treatment
commenced on Day 4 following implantation (N.B.: ordinate is logarithmic).
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0-* CYCLOPHOSPHAMIDE 100mg/kg
0-0 CYCLOPHOSPHAMIDE 100mg/kg
with ADRIAMYCIN 10 mg/kg
ASCITIC FLUID
4 6
LIVER
6
TIME (h)
FIG. 3.-Alkylating activity in liver and ascitic fluid following treatment with CTX alone or in com-
bination with ADR, as a function of time from treatment.
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z
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-C 40 - ADRIAMYCIN 1omg/kg with
CYCLOPHOSPHAMIDE 100mg/kg
z
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FiG. 4.-Adriamycin levels in liver and ascitic fluid following treatment with ADR alone or in com-
bination with CTX, as a function of time from treatment.
lents in the liver and ascitic fluid following
treatment either with the single agents or
the agents in combination. There is no
major difference either in the curves for
alkylating activity or the curves for total
adriamycin fluorescence, irrespective of
whether the agent was given alone or in
combination with the other drug.
Adriamycin/melphalan treatment of L1210
leukaemia
The dose response for LI210 leukaemia
treated with a combination of ADR and
L-PAM is shownin TableV. Pilot studies
had confirmed that the optimal single dose
of L-PAM was 15 mg/kg although at this
dose there were no long survivors. The
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TABLE V.-Dose-Response for ADR and
L-PAM Alone and in Combination. Results
Expressed as Increase in Life Span (lLS)
ADR
(mg/kg)
0 2-5
0 +27
5 0 +36 +54
L-PAM 7 - 5 +45 + 73
(mg/kg) 10- 0 + 73 + 82
15-0 +91 *
(4/7)
20- 0 -18 N.D.
5 0
+27
+ 54
+ 82
+73
*
(4/7)
N.D.
10-0
+36
+73
+ 100
+ 54
N.D.
N.D.
20-0
-18
-18
N.D.
N.D.
N.D.
N.D.
n= 7 animals/group.
Median day of death for 19 controls= 11.
* ILS not available as greater than 50% of
animals survived.
= number of surviving animals.
N.D. =Not done.
addition of adriamycin led to a survival
of greater than 50% in 2 groups.
DISCUSSION
The considerable effectiveness of CTX
in L1210 leukaemia has been recognized
for many years and studied extensively
(Skipper, Schabel and Wilcox, 1964).
Other alkylating agents, including L-PAM,
are also active in this experimental tumour
(Goldin and Carter, 1973). ADR, the
most promising of the anthracyclene
drugs, has been disappointing in this
tumour despite its very wide spectrum
of activity in other experimental tumours
and in a number of human malignancies
(Southern Research Institute, unpublished
data; Blum and Carter, 1974) ADR has
been shown to be a useful drug in com-
bination with CTX for a number of
tumours (Corbett et al., 1975) not including
L1210, and the combination has been
investigated in a Phase I study as well
as in two further disease-specific studies
(Muggia et al., 1974; Salmon and Jones,
1974; Parker et al; 1975). The results
of the present study are as follows:
(i) Over half of all
ADR/CTX at Day
are long survivors.
achieve cure with
animals treated with
4 following 105 cells
It is not possible to
either CTX or ADR
alone when treatment is commenced on
Day 4.
(ii) The synergy is not dependent on the
schedule or sequence of administration
of ADR and CTX.
(iii) The combination of CTX and ADR
is no longer synergistic if treatment is
delayed till Day 6. In this situation the
optimal dosage of CTX alone gives com-
parable results with the combination
treatment.
(iv) The synergism is all the more remark-
able in view of the relative ineffectiveness
ofADR as a single agent in the treatment
of L1210 leukaemia. In general, agents
which are not effective in experimental
tumours are alsoofnovalueincombination
treatment programmes (F. M. Schabel,
personal communication).
(v) The increased survival in the groups
treated by combination therapy is explic-
able on the basis of almost complete
inhibition of DNA synthesis. Both
depth and duration of the inhibition of
DNA synthesis is far greater for the
tumour than the host cell. Reduction
in the total ascitic cell population is more
rapidandmorecompleteinthecombination
treated animals. The effectiveness of
the ADR/CTX combination is not due
to any change in the general pharmaco-
logical distribution of either agent. No
major pharmacological differences were
seen, irrespective of whether the agents
were administered singly or together.
(vi) The combination ofADR and L-PAM
in L1210 produces wperior results to
those obtained using either drug alone
at optimal dosage. This suggests that the
ADR/CTX synergy is not specific and
that use ofanother alklating agentinstead
of CTX might also lead to encouraging
results in the clinic. In view of the lesser
gastrointestinal and genitourinary toxicity
of L-PAM by comparison with CTX, this
combination ought to be better tolerated
in man. Both ADR and L-PAM are
active agents in carcinomata of the breast
(Ahmann et al., 1974; Fisher et al., 1975)
and ovary (Smith and Rutledge, 1970;
de Palo et al., 1974), and a Phase I clinical
206ADR/CTX AND ADR/L-PAM IN ADVANCED L1210 LEUKAEMIA 207
trial of this combination should be
undertaken.
There are a number of possible explan-
ations for the synergy demonstrated
here. It is conceivable that adriamycin
may interfere with DNA repair following
CTX- or L-PAM-induced damage. It is
possible that the ability ofCTX or L-PAM
to act as an alkylating agent may be
enhanced by the presence of ADR due to
increased receptivity oftheADR damaged
molecule. These and other potential
mechanisms warrant further study.
We are grateful to Barbara Brown
and Margaret Hirst for excellent technical
assistance; and to Dr D. W. Yesair and
Suzanne McNitt of Arthur D. Little Inc.,
Cambridge, Mass., for collaboration in the
pharmacological studies (supported in part
by Contract No. 1-CM-5-3849).
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